TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Presence of anti-La antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of sertraline versus imipramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Split times for the 25- to 50-m distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First 50-m stroke rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of laryngeal examination by the clinician
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased collagen production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen fibril morphology changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: systolic blood pressure, diastolic blood pressure, and mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of ischaemic foot ulcers
Endpoint domain: Mortality/survival
Primary endpoint: Stimulated blood flow (perfusion units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Renin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Admissions to hospital for asthma
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Attendance at the Children's Emergency Department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prescriptions for oral relievers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Provocative dose of methacholine causing a 20% decline in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incision to delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average personal noise exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Torque Decrements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of Torque Development and Relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: RPE Leg Values
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: plasma and LDL apoCIII concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total nasal scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Index of Erectile Function (IIEF) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intercourse success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in low-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in fasting homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvements in diastolic and systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-procedure pain and anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: task-specific checklist score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of SAP and RF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic growth scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PTSD symptom decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood lead levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythrocyte GSH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythrocyte G6PD activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cortical vBMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortical area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortical thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for T2DM
Endpoint domain: Mortality/survival
Primary endpoint: RV function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS score for stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective global function score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in being UTD with CRC screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic cerebrospinal venous insufficiency criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MR imaging measures of intracerebral flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: TEWL values recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SC moisture (capacitance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: decrease in costs of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease in detrusor pressure at maximum flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in obstructive and irritative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year recurrence-free rate
Endpoint domain: Mortality/survival
Primary endpoint: Central epithelial thickness (ET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of substance abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in MADRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature withdrawal from treatment
Endpoint domain: Adverse events/effects
Primary endpoint: fragmentation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: day 90 modified Rankin Scale (0-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postsurgical cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total cost of therapy for nosocomial pneumonia
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of neurological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of study withdrawals due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of sublingual immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of sublingual immunotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: DO2 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2,IC increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2,Fick increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of boys with insulin resistance (IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fat mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RV‐IgA geometric mean concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of RVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative pain severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of residual hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative survival after D4 resection
Endpoint domain: Mortality/survival
Primary endpoint: Proportions who remained in the best category of cerebral performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Endurance running performance (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of rocuronium injection pain
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of rocuronium injection pain
Endpoint domain: Adverse events/effects
Primary endpoint: 4-week binge eating cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement in pulse and triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PANSS negative factor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: persistent sleep problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement in vision of flexible cystoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient discomfort (pain scores)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in overall appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface gloss of composite materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPSO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CASO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFSO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident sexually transmitted diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incident HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ICH expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Decrease in opioid medication prevalence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tension scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: barrier disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of probing depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in attachment levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transpulmonary pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional Recovery outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean 24-hour average PI-NRS pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD-RS total scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-I ratings distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: INR values within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean effect-site concentration of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean effect-site concentration of fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma phosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH‐CPSI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average waiting time of NIH‐CPSI variation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hepatic steatosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Insulin resistance (serum glucose and HOMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lobular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Adrenal gland perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noradrenaline plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid-positive urine screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of self-reported heroin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recolonization of catheter-surrounding skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Catheter-related blood stream infection (CRBSI)
Endpoint domain: Adverse events/effects
Primary endpoint: intercellular adhesion molecule‐1 (sICAM‐1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self-perception of appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: subjective scoring of appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood product consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of CRP treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dependence on medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complications of CRP treatment
Endpoint domain: Adverse events/effects
Primary endpoint: improvements in skin condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of debris in root canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft failure and displacement
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of bacteraemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Standard deviation of R-R intervals (SDRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraoperative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Primary safety outcomes at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: usefulness rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CCA-IMTmean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in femoral artery IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in SiSBP and SiDBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of endotoxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Epworth Sleepiness Scale (ESS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Maintenance of Wakefulness Test (OSLER) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery of circulating erythrocyte mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete healing defined as absence of inflamed sites > or =5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood product requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual read accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-rated child impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fruit and vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incision healing without complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean score for clinical presentations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Permanently restoring blood coagulability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioequivalence of levothyroxine preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-nicotine substance use days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of preeclampsia at less than 27 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Onset of preeclampsia at less than 37 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: rate of locoregional recurrence
Endpoint domain: Mortality/survival
Primary endpoint: relative rate of distant recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of spinal headaches
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Retention of factual knowledge of obstetric emergencies care
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prednisolone area under the curve (AUC)-dose-normalized (PNAUCn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of casein-specific IgE antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of whole milk-specific IgE antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery and relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Disorder Examination Questionnaire (EDE-Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision Functioning Quality of Life (VFQoL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total power (variance) of heart rate variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LF/HF power ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dosing accuracy errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung deposition fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inner-outer ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Apical-basal ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 5-year probability of cancer-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: 5-year probability of relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: 5-year probability of local recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in self-management questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: composite disease activity indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: assessment of physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: X-ray progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: revision surgery required
Endpoint domain: Adverse events/effects
Primary endpoint: Sense of Coherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychological subscale of the WHO Quality of Life scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Requirements of rescue analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: thyroglobulin antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes